Insulin like growth factor binding protein bioactive peptide fragments

Abstract

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

What is claimed is: 
     
         1 . An isolated peptide having a length of 7 amino acids to 20 amino acids and comprising an amino acid sequence having at least 65% sequence identity to SEQ ID NO: 2. 
     
     
         2 . The peptide of  claim 1  comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 2. 
     
     
         3 . The peptide of  claim 1  having a length of 7 amino acids to 20 amino acids and comprising an amino acid sequence of PKKLRP (SEQ ID NO: 2). 
     
     
         4 . An isolated peptide consisting of an amino acid sequence of PKKLRP (SEQ ID NO: 2). 
     
     
         5 . The peptide of  claim 1 , further comprising N-terminal carboxylation, C-terminal amidation, one or more halogens, or a combination thereof. 
     
     
         6 . The peptide of  claim 1 , wherein the peptide is cyclized. 
     
     
         7 . A pharmaceutical composition comprising a peptide of  claim 1  and at least one pharmaceutically acceptable excipient. 
     
     
         8 . A method of treating depression in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of  claim 1 . 
     
     
         9 . A method of treating post-traumatic stress disorder (PTSD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of  claim 1 . 
     
     
         10 . A method of treating a central nervous system disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of  claim 1 . 
     
     
         11 . The method of  claim 10 , wherein the central nervous system disorder is selected from autism spectrum disorders, bipolar disorder, catalepsy, depression, post-traumatic stress disorder (PTSD), encephalitis, epilepsy/seizures, locked-in syndrome, meningitis, migraine, multiple sclerosis, myelopathy, neurodegenerative disorders, schizophrenia, obsessive-compulsive disorder, and tic disorders, or any combination thereof. 
     
     
         12 . A method of treating a neurodevelopmental disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of  claim 1 . 
     
     
         13 . The method of  claim 12 , wherein the neurodevelopmental disorder is selected from intellectual disability, autism spectrum disorders, motor disorders, tic disorders, traumatic brain injury, Down syndrome, attention deficit hyperactivity disorder, schizophrenia, schizotypal disorder, hypogonadotropic hypogonadal syndromes, fetal alcohol spectrum disorder, and Minamata disease caused by mercury, or any combination thereof. 
     
     
         14 . The method of  claim 13 , wherein the autism spectrum disorders are classical autism or Autistic Disorder; Asperger Syndrome; Childhood Disintegrative Disorder; Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS); Fragile X Syndrome; Rett Syndrome; Kanner syndrome; or Phelan-McDermid Syndrome. 
     
     
         15 . The method of  claim 13 , wherein the motor disorders are developmental coordination disorder or stereotypic movement disorder. 
     
     
         16 . A method of treating Phelan-McDermid Syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide of  claim 1 . 
     
     
         17 . An isolated peptide having a length of 18 amino acids to 40 amino acids, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1. 
     
     
         18 . The peptide of  claim 17  comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1. 
     
     
         19 . The peptide of  claim 17  comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1. 
     
     
         20 . The peptide of  claim 17  having a length of 18 amino acids to 40 amino acids, comprising an amino acid sequence of KHGLYNLKQCKMSLNGQ (SEQ ID NO: 1).